EMA Gets Specific On Pharmacovigilance Of Drugs Used In Pregnancy
Draft Guideline Issued After Three Year Delay
Executive Summary
A new EU guideline offers recommendations for facilitating appropriate pharmacovigilance for drugs that may be used in pregnant or breastfeeding women.
You may also be interested in...
EMA Aims For Better Info On Benefit-Risk Balance To Support Drug Choices In Pregnancy
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
Need For Consensus On Pharmacovigilance For Drugs In Pregnancy Delays New EMA Guideline
A new draft guideline from the European Medicines Agency on pharmacovigilance requirements relating to medicines taken during pregnancy and breastfeeding has been delayed and will now be issued for stakeholder consultation by the end of 2017.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.